Helpful Berinert Resources CSL Behring provides helpful resources for healthcare professionals that can support your patients' use of Berinert.

Berinert Insurance Verification Request-Prescription Referral Form Berinert Referral Form

Download the Berinert Referral Form. For assistance, call B.E.N. toll free 24/7 at 1-877-BEN-4HAE (1-877-236-4423).

Berinert Expert Network (B.E.N.) Patient Enrollment Form B.E.N. Enrollment Form

The Berinert Expert Network (B.E.N.™) is available to help you and your staff 24 hours a day, 7 days a week. Download this form to enroll, or call B.E.N. toll-free at 1-877-BEN-4HAE (1-877-236-4423).

Differential Diagnosis Tool - 8 Questions to help differentiate between allergic angioedema, acute abdomen, and HAE. Differential Diagnosis Tool

Ask your patients these 8 questions to help differentiate between allergic angioedema, acute abdomen, and HAE.

Berinert Coding Guide for Healthcare Professionals Coding Guide

Click here to obtain the diagnosis coding and determination of the appropriate ICD-9-CM code that describes the patient's condition.

Self administration videoBerinert C1 Esterase Inhibitor, Human On-Demand Treatment Self-Administration Video Instructional Self-Administration Video

After receiving proper training, your patients can watch this video to help guide them through the selfadministration process.

Berinert Self-Administration Step-by-Step Slide Show Self-Administration Slideshow

After receiving proper training, your patients can use this step-by-step slideshow to help guide them through the self-administration process.

Additional Resource Links

HAE and You: A Resource for Families with Hereditary Angioedema
Hereditary angioedema support and information for family members, friends, teachers, school nurses, and others who may come in contact with people who have this rare condition.

US Hereditary Angioedema Association Website
HAE patient organization and community that provides peer-to-peer support, physician referrals, education, and patient resources.

Save on Co-Pays: The Berinert Co-Pay BENefit™ may cover up to $12,000 of your eligible out-of-pocket expenses per year.

Download Enrollment Form »

Answers to health care providers' most frequently asked questions about hereditary angioedema and patient self-administration training.

Home Resources

Important Safety Information

BERINERT®, C1 Esterase Inhibitor (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (Human), indicated for the treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric patients. The safety and efficacy of BERINERT for prophylactic therapy have not been established.

BERINERT is contraindicated in individuals with a history of life-threatening systemic reactions to C1 esterase inhibitor preparations (including anaphylaxis).

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis). If hypersensitivity is suspected, immediately discontinue administration of BERINERT and initiate appropriate treatment. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reactions.

Serious arterial and venous thromboembolic (TE) events have been reported following administration of recommended doses of C1 Esterase Inhibitor (Human) products to patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device; prior history of thrombosis; underlying atherosclerosis; use of oral contraceptives or certain androgens; morbid obesity; and immobility. Weigh benefits/risks before administering to patients with known risk factors for TE events and closely monitor such patients during and after BERINERT administration. TE events also have been reported with C1 Esterase Inhibitor (Human) products when used for unapproved indications at higher than recommended doses.

Appropriately trained patients may self-administer BERINERT upon recognition of an HAE attack. Advise patients to seek medical attention immediately following selfadministration for laryngeal attacks, and to seek medical attention if progress of any attack makes them unable to properly prepare or administer dose of BERINERT.

BERINERT is derived from human plasma. The risk of transmission of infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

The most serious adverse reaction reported in subjects who received BERINERT in clinical studies was an increase in severity of pain associated with HAE. Dysgeusia was the most common adverse reaction reported in over 4% of subjects and more frequently than in the placebo group.

BERINERT has not been evaluated in pregnant women or nursing mothers, and should be used only if clearly needed. In clinical trials, the half-life of BERINERT was shorter and clearance was faster in children than in adults; the clinical implication of this difference is not known.

Please see full prescribing information for BERINERT, including the patient product information.

CSL Behring
© 2018 CSL Behring. The product information presented on this site is intended for US residents only. BRN/03-13-0059(1)d